entertainment -WSS

entertainment

author：entertainment 2025-09-30 17:03:01 - browse：3

Three boxes of Breyanzi on a dark blue background — biotech coverage from STAT — The FDA is looking into adverse events involving a number of CAR-T therapies, including Breyanzi. Illustration: STAT; Source: Business Wire

The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which uses genetically modified white blood cells to attack tumors, can in rare cases cause lymphoma, a blood cancer.

“Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action,” the agency said in a statement.

The agency noted that it is investigating reports of T cell lymphoma, including cancer cells carrying the engineered T cells, in patients who received CAR-T therapy. Experts in the field, which has produced multiple approved products to treat blood cancer, expressed surprise and puzzlement at the announcement, saying that they had not previously seen data about the risk.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Studies point to risks of excluding people with obesity from drug trials

WSS

Indictment alleges Trump's ex

STAT Summit: Michael J. Fox on progress in Parkinson's research

Biogen’s boardroom scandal saddles CEO with first crisis

Senators push IRS to launch nonprofit hospital probe

Eli Lilly expects to double planned employment in Boston center

Medicare reduced heart disease by changing how it pays doctors

focus

entertainment

hotspot

The high cost of giving birth even with insurance

Mark Cuban is blaming the wrong people for high drug costs

Medical records are filled with copy

After Optum profits sink, UnitedHealth makes changes

Continuity nursing helped my family in our darkest PICU moments

STAT Summit: Michael J. Fox on progress in Parkinson's research

Bright Health sells Medicare Advantage business to Molina

Illumina slashes 2023 revenue projections yet again

Drug repurposing or repositioning? The language matters

YouTube cracks down on misinformation on cancer treatment

entertainment

Novo Nordisk touts Wegovy study, but still struggling with supply

Medicare reduced heart disease by changing how it pays doctors

Solve the antibiotic resistance crisis with preventive drugs

Idaho college killings prosecutors challenge defense's grand jury claims

Montana youths win climate lawsuit against state for promoting fossil fuels

Senate committee scrutinizes Medicare Advantage brokers

hotspot

focus

focus

knowledge